A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

Inclusion criteria: This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated RET positive non-small cell lung cancer (NSCLC).

Sponsor/Collaborator: Genentech, Inc.|Blueprint Medicines Corporation|Chugai Pharmaceutical Co.|Hoffmann-La Roche

Contact and Locations:
Reference Study ID Number: ML41591
Email: global-roche-genentech-trials@gene.com
Phone Number: 888-662-6728
Locations: https://clinicaltrials.gov/study/NCT04302025#contacts-and-locations

Mechanism of action: Pralsetinib is a highly potent, selective RET inhibitor for the treatment of patients with cancers that harbor abnormalities in the RET kinase.

Phases: Phase 2

NCT Number: NCT04302025

Status: Recruiting

Back to clinical trials list